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The Drug-Induced Liver Injury Network (DILIN) studies hepatotoxicity caused by con-
ventional medications as well as herbals and dietary supplements (HDS). To characterize
hepatotoxicity and its outcomes from HDS versus medications, patients with hepatotox-
icity attributed to medications or HDS were enrolled prospectively between 2004 and
2013. The study took place among eight U.S. referral centers that are part of the
DILIN. Consecutive patients with liver injury referred to a DILIN center were eligible.
The final sample comprised 130 (15.5%) of all subjects enrolled (839) who were judged
to have experienced liver injury caused by HDS. Hepatotoxicity caused by HDS was
evaluated by expert opinion. Demographic and clinical characteristics and outcome
assessments, including death and liver transplantation (LT), were ascertained. Cases were
stratified and compared according to the type of agent implicated in liver injury; 45
had injury caused by bodybuilding HDS, 85 by nonbodybuilding HDS, and 709 by
medications. Liver injury caused by HDS increased from 7% to 20% (P< 0.001) during
the study period. Bodybuilding HDS caused prolonged jaundice (median, 91 days) in
young men, but did not result in any fatalities or LT. The remaining HDS cases pre-
sented as hepatocellular injury, predominantly in middle-aged women, and, more fre-
quently, led to death or transplantation, compared to injury from medications (13% vs.
3%; P< 0.05). Conclusions: The proportion of liver injury cases attributed to HDS in
DILIN has increased significantly. Liver injury from nonbodybuilding HDS is more
severe than from bodybuilding HDS or medications, as evidenced by differences in
unfavorable outcomes (death and transplantation). (HEPATOLOGY 2014;60:1399-1408)
A
pproximately half the U.S. adult population
consumes herbals and dietary supplements
(HDS),1,2 with recent reports showing their use
to be increasing.1,3 Supplement users are more com-
monly women, non-Hispanic whites, over age 40, and
have higher levels of education than nonusers.3-6
National Health and Nutrition Examination Survey
(NHANES) III data indicate that multivitamins and
minerals are the most common supplements used, fol-
lowed by calcium and fish oils.4 However, the range of
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HDS is far broader and includes numerous commer-
cial products.
Although dietary supplements are perceived as safe,7
the current regulatory framework established by the
Dietary Supplement Health and Education Act of
19948 requires less evidence of safety before marketing
as assessed by the U.S. Food and Drug Administration
(FDA) than is required for pharmaceuticals. The FDA
and other regulatory bodies can take action against a
manufacturer only if there is proven adulteration or
injury from its supplement. Recent cases of life-
threatening hepatotoxicity from the dietary supple-
ment, OxyElite Pro,9 underscore the potential adverse
consequences of this oversight process.
The Drug-Induced Liver Injury Network (DILIN),
supported by the National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK), was estab-
lished in 2003 to identify, enroll, and characterize cases
of drug-induced liver injury (DILI) attributable to
medications (excluding acetaminophen [APAP]) and
HDS (ClinicalTrials.gov Identifier: NCT00345930).10
The original DILIN report identified HDS as the
second-most common cause for liver injury.11 Since
that report, many more cases have been accrued by the
DILIN. Thus, we examined the burden and character-
istics of liver injury attributable to HDS in the DILIN
and compared this injury with that caused by conven-
tional medications.
Patients and Methods
Study Design. The DILIN investigators (see Appen-
dix) prospectively enrolled consecutive cases of suspected
non-APAP hepatotoxicity. Enrollees were asked to sign
written informed consent before enrollment. The study
protocol conformed to the ethical guidelines of the 1975
Declaration of Helsinki as reflected in a priori approval
by each institution’s review committee.
Inclusion Criteria and Patient Ascertainment
Procedures. Patients had to be at least 2 years of age
at enrollment and suspected of having experienced
DILI within the preceding 6 months.10 Inclusion crite-
ria were jaundice (total bilirubin: 2.5 mg/dL) or coa-
gulopathy (international normalized ratio >1.5) with
any elevations in alanine or aspartate aminotransferase
(ALT or AST) or alkaline phosphatase (ALP) levels,
respectively, or absent jaundice or coagulopathy, eleva-
tions of ALT or AST above 5 times the upper limit of
normal (ULN) or ALP above 2 times ULN on two
consecutive measurements at least 24 hours apart. For
patients with documented hepatic biochemical test
abnormalities preceding the onset of hepatotoxicity,
the ALT or AST must have been above 5 times the
baseline value, or ALP above 2 times the baseline
value, on two consecutive measurements. Injury onset
was the date when inclusion criteria were met.
Patients were evaluated for the differential diagnostic
possibilities of nondrug liver diseases. This included test-
ing for serological markers of viral and autoimmune
hepatitis (AIH) and for metabolic and inherited blood
markers, including serum ceruloplasmin, iron studies
(serum iron, total iron-binding capacity, and ferritin),
and alpha-1-antitrypsin level; hepatic imaging was also
required. Liver biopsies were assessed, when available,
for diagnostic and causality assessment purposes. Patients
underwent physical examinations by physician investiga-
tors and were queried using standard data collection pro-
cedures on the chronological use of all drugs and HDS,
as well as on comorbid conditions and alcohol use.
Exclusion criteria included liver injury caused by APAP,
AIH, primary biliary cirrhosis, primary sclerosing chol-
angitis, or other chronic biliary tract disease. Also
excluded were patients who had undergone liver or allo-
geneic bone marrow transplantation before injury onset.
The presence of chronic hepatitis B or C or of human
immunodeficiency virus infection were not reasons for
exclusion from enrollment or adjudication.
Causality Assessment and Outcomes. As described
previously, a standardized protocol was used to assess
the relationship between the use of a medication or
HDS and liver injury.10 The first task was to assess
whether liver injury was likely to be a result of hepato-
toxicity through review of diagnostic information by the
clinical investigator responsible for the case and two
additional investigators and then whether the medica-
tion or HDS might have been responsible. In the case
of medications, if more than one had been used and
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hepatotoxicity appeared likely, each was scored inde-
pendently for the likelihood of causality, relative to the
other medications consumed. Causality was graded by
the three investigators; consensus was achieved by means
of email discussion. When the three did not reach con-
sensus, there was detailed consideration of the case by
the full DILIN Committee on Causality Assessment, a
larger group of experienced hepatologists, drawn from
all eight clinical centers, the data coordinating center
(Duke University, Durham, SC), and the NIDDK
through a conference call. The final scores were definite
(>95% likelihood), highly likely (75%-95%), probable
(50%-74%), possible (25%-49%), or unlikely (<25%).
Compared to conventional medications, adjudicating
HDS was more complex because several products may
have been used simultaneously, most containing multi-
ple ingredients. Accordingly, HDS taken by any patient
were grouped together and adjudicated as a single agent,
even if several were taken concurrently.
Analysis of the cases was confined to those in which
causality assessment was graded as probable, highly
likely, or definite. If both medications and HDS were
implicated, HDS was selected as the culprit only if all
adjudication criteria indicated it to be a more likely
cause for injury than the medication(s). Outcomes from
liver injury events were assessed as liver-related death or
liver transplantation (LT) occurring at any time after
onset of liver injury. Rates of hospitalization were com-
pared among the groups. Additionally, a severity score
(DILIN Severity Score) was assigned as 1 of 5 levels, as
previously described: mild, moderate, moderate-
hospitalized, severe, and fatal/transplant.10 A binary out-
come of severe versus not severe was created for analysis
by combining the severe and fatal/transplant cases into
the severe category, as shown in Table 2.
Liver Injury Patterns. The “R” ratio, by conven-
tion, describes the pattern of liver injury as hepatocellu-
lar, cholestatic, or mixed. Specifically, the R value is
calculated from the ratio of serum ALT to serum ALP,
both expressed as multiples of the ULN.12 The ratio was
calculated using laboratory values at the onset of injury.
Implicated HDS and Categorization of Patients.
Two authors (V.N. and J.S.) divided the patients with
liver injury caused by HDS into two broad categories:
those with injury from bodybuilding HDS and those
with injury from nonbodybuilding HDS. The ration-
ale for this separation was that bodybuilding products
accounted for the largest subgroup among those with
hepatotoxicity from HDS with certain prima facie dis-
tinguishing features (e.g., predominantly men, pro-
longed jaundice, and eventual recovery), whereas
nonbodybuilding HDS produced injury that varied
widely, as did the clinical features among the subjects.
Classification into bodybuilding or nonbodybuilding
HDS product type was based on review of product
label and internet marketing information.
Data from three groups were compared: patients
with hepatotoxicity from bodybuilding HDS; nonbo-
dybuilding HDS; and conventional medications. To
avoid overlap among groups, patients were excluded if
they had used both bodybuilding and nonbodybuild-
ing HDS together or if both a medication and HDS
were implicated and thought to be equally likely to
have caused the injury.
Statistical Analysis. Continuous data were sum-
marized with median values and interquartile ranges.
Categorical data were summarized with frequency and
percentage. Kruskal-Wallis’ and Fisher’s exact tests were
used to compare the groups for continuous data and
categorical data, respectively. Time-to-event analysis
was used to compare course of liver injury (days from
peak enzyme value to 50% of its peak value) between
the groups where median and interquartile times were
estimated. Cochran-Armitage’s test for linear trend was
carried out to investigate temporal trends in liver
injury. Multivariate logistic regression models were car-
ried out for dichotomous outcome of LT and DILIN
severity score to determine the adjusted group effects
after adjusting for clinical and demographical variables
that were different between the groups. Model selec-
tions were carried out based on step-wise, backward,
and forward procedures as well as manual selection
based on clinical input. The final models were used
for reporting. A P value of 0.05 or less was considered
statistically significant. All statistical analyses were car-
ried out by Statistical Analysis Software (SAS; version
9.3; SAS Institute Inc., Cary, NC) and were performed
by one author (H.B.). All authors contributed to inter-
pretation of the data.
Results
Liver Injury Cases. As of March 2013, 1,219
patients with liver injury from medications, HDS, or
both were enrolled; 1,035 completed causality assess-
ment and were eligible for inclusion in this study
(Fig. 1). Among these, 847 (82%) were adjudicated as
probable, highly likely, or definite; 2 were excluded
because both medications and HDS were assessed as
equally likely to be the cause for hepatotoxicity, and 6
were excluded because both bodybuilding and nonbo-
dybuilding HDS were implicated. Among the remain-
ing 839 patients included in the final analysis, 709
(85%) had liver injury from medications and 130
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(15.5%) injury from HDS. The 130 patients with
liver injury from HDS consisted of 45 (35%) who had
taken bodybuilding HDS and 85 (65%) who had
taken nonbodybuilding HDS.
Demographic Characteristics. Demographic char-
acteristics are shown in Table 1. Patients with liver
injury attributed to bodybuilding HDS were younger,
compared to those with injury from nonbodybuilding
HDS and medications (median age: 31 vs. 47 vs. 52
years, respectively; P< 0.001) and were exclusively
male (100% vs. 35% vs. 37%, respectively;
P< 0.001). Liver injury from nonbodybuilding HDS
involved non-Hispanic whites and non-Hispanic blacks
less frequently (P5 0.002) and Hispanic/Latinos more
frequently (P< 0.001) than did injury attributed to
either bodybuilding HDS or medications.
Temporal Trends in Liver Injury. The proportion
of patients with liver injury from HDS in the DILIN
registry increased during the study at a greater rate than
that of injury ascribed to conventional medications.
Specifically, 7% of DILIN cases were attributed to
HDS during the first 2 years of the registry, compared
to 20% 10 years later (P5 0.0007; Fig. 2); the increase
involved both bodybuilding HDS (from 2% in 2004-
2005 to 8% in 2010-2012; P5 0.007) and nonbody-
building HDS (from 5% in 2004-2005 to 12% in
2010-2012; P5 0.05). Liver injury cases were grouped
by 2-year enrollment cohorts, although patients enrolled
during 2012 were included with the final cohort
because of the small number that had completed the
causality assessment process preceding analysis. The
increased rate of liver injury from nonbodybuilding
HDS resulted mainly from a disproportionate increase
in cases enrolled at two metropolitan centers (Los
Angeles, CA, and Philadelphia, PA). Of the total 213
cases in 2010-2012, these two centers had 19 (23%)
Fig. 1. HDS case enroll-
ment, 2004 to 2013.
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nonbodybuilding cases of the 82 confirmed cases, as
compared to 18 (8%) nonbodybuilding cases of 232
confirmed cases in the other six centers (P< 0.001).
Liver Injury Outcomes. LT was required more fre-
quently among patients with injury from nonbody-
building HDS than with hepatotoxicity from
conventional medications (13% vs. 3%, respectively,
P< 0.001; Table 2). This difference remained statisti-
cally significant (P5 0.001) after adjusting for clinical
and demographical variables that were different among
the groups in a multivariate logistic regression analysis.
The considered covariates were age, sex, race, Hispanic
ethnicity, weight, history of allergy, alcohol consump-
tion, history of diabetes mellitus, history of neurologi-
cal disease, history of heart disease, history of renal
disease, history of pulmonary disease, history of gastro-
intestinal (GI) disease, history of malignancy, history
of congestive heart failure, and any comorbid condi-
tion. Only race and weight remained statistically sig-
nificant in addition to group assignment (i.e.,
bodybuilding, nonbodybuilding, or conventional medi-
cation injury group) in the final logistic regression
model. No patients with hepatotoxicity attributed to
bodybuilding HDS died as a result or required LT.
Hospitalization rates did not differ among the groups.
These observations remained unchanged even after
excluding from the analyses those patients with pre-
existing comorbid conditions (data not shown).
A total of 13 patients underwent LT or died in the
nonbodybuilding HDS group (1 patient had LT and
then died). Their mean age was 56 years (range, 27-
73), All 13 were female, and 9 (69%) were white
(Table 3). Not surprisingly, patients with more-severe
hepatocellular injury (R value >5) progressed to LT
more quickly than did those with cholestatic/mixed
liver injury (median [range] days from onset to death/
transplant was 28 [2-77] vs. 234 [61-263] in choles-
tatic/mixed group; P5 0.004). Two of three patients
who died had cholestatic/mixed injury. Two of the
three deaths were attributed to the liver injury and the
remaining death occurred as a result of an endoscopic
procedural complication.
The HDS liver injury group was found to have a
significantly higher proportion of severe cases, based
on the DILIN severity score, than the conventional
medications liver injury group (P5 0.02). The
adjusted group difference in severity score among the
three groups remained statistically significant (P5 0.04
for bodybuilding HDS vs. conventional medications and
P5 0.007 for nonbodybuilding HDS vs. conventional
medications) after adjusting for baseline clinical and
demographical variables that were considered for the
DILIN severity score model. Only age, alcohol con-
sumption, history of renal disease, and history of conges-
tive failure remained statically significant in addition to
group indicators in the final logistic regression model.
Clinical Characteristics. Patients with hepatotox-
icity from bodybuilding HDS were heavier, but with-
out significant differences in body mass index (BMI),
Table 1. Demographic Characteristics of the Subject Population
Characteristic Total (n5 839)
Liver Injury Caused by
Bodybuilding
HDS (n5 45)
Liver Injury Caused by
Nonbodybuilding HDS
(n5 85)
Liver Injury Caused by
Conventional Medications
(n5 709) P Value
Age, median 50 31 47 52 <0.001
(25th, 75th) (37, 61) (26, 37) (38, 61) (39, 62)
Gender (%) <0.001
Male 337 (40) 45 (100) 30 (35) 262 (37)
Female 502 (60) 0 (0) 55 (65) 447 (63)
Race (%)
Non-Hispanic white 657 (78) 37 (82) 57 (68) 563 (80) 0.002
Non-Hispanic black 97 (12) 5 (11) 7 (8) 85 (12)
Hispanic 87 (10) 6 (13) 20 (24) 61 (9) <0.001
Fig. 2. Temporal Trends in DILIN Enrollment. Light gray bar repre-
sents medications, medium gray bar represents nonbodybuilding HDS,
and dark gray bar represents bodybuilding HDS.
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compared to other groups, presumably because all
were males with a greater muscle mass (Table 4) and
weight was significantly different between the groups
after adjusting for gender (P5 0.6). They also had dis-
tinctive clinical symptoms, in that all were jaundiced
(P< 0.001) and most (84%) had pruritus (P< 0.001).
Comorbid conditions were less common among
patients with injury from bodybuilding HDS, compared
to the other two groups (21% vs. 53% vs. 69%, respec-
tively, P< 0.001; Table 4). Not surprisingly, diabetes
and neurological, heart, pulmonary, and GI disease were
more common among patients with conventional
medication-associated liver injury (P< 0.001, 0.007,
<0.001, 0.009, and <0.001, respectively). Conversely,
alcohol use was more frequent in the bodybuilding
group than in the nonbodybuilding or medication
groups (79% vs. 54% vs. 48%, respectively; P< 0.001).
At presentation, patients with injury from bodybuild-
ing HDS had the lowest median values for serum ALT
(173 U/L), AST (82), and ALP (116 U/L), but the
highest total bilirubin levels (9.8 mg/dL; P< 0.001 for
all liver tests). In contrast, patients with injury from non-
bodybuilding HDS had the highest mean ALT (1,019
U/L) and AST (815 U/L) values and intermediate mean
ALP (212 U/L) and bilirubin levels (7.5 mg/dL). Patients
with medication-induced injury had intermediate ALT
and AST elevations (505 and 319, respectively), as well
as the highest ALP and lowest bilirubin levels.
The pattern of liver injury in those using body-
building HDS resembled that of bland cholestasis,
Table 3. Cases of Death or LT Resulting From Liver Injury Caused by Nonbodybuilding HDS
Case Age Gender
Race/
Ethnicity Product Name
Main Marketed
Purpose for Use
Clinical
Pattern (R Value)
Death or
Transplant
Days From
DILI Onset to
Death/Transplant
1 49 Female White Up Your Gas Energy Booster Energy booster Hepatocellular (10) Transplant 77
2 45 Female White CVS Spectravite Performance Multivitamin Hepatocellular (20) Transplant 16
3 34 Male White Mega Pro Vasopro Ephedrine Nasal congestion Hepatocellular (63) Transplant 2
4 64 Male White Chinese Herbal Viagra Sexual performance Cholestatic (1) Transplant 234
5 27 Female Latino 1) Slimquick
2) Ripped Fuel “Extreme” Ephedra Free
Weight loss Hepatocellular (30) Transplant 13
6 66 Male Asian Chinese Herbs Unknown Hepatocellular (30) Transplant 5
7 58 Female White Symmetry Ultra Vitality Multivitamin Cholestatic (<1) Transplant 252
8 62 Male White 1) Swanson Premium Brand DHEA
2) Swanson Passion Tongkat Ali
(Eurycoma Longifolia)
3) Swanson Kyoto Oyster Extract
Sexual performance Hepatocellular (37) Transplant
and Death
33
9 71 Male White 1) Complete Natural Products-Gallbladder
Complete
2) Native American Nutritionals Ph Rescue
Miscellaneous Cholestatic (<1) Death 61
10 73 Female Asian Chinese Herbs Unknown Hepatocellular (8) Transplant 57
11 64 Male White Unknown Herbal Tablet from Thailand Unknown Cholestatic (1.2) Transplant 234
12 56 Male Multiracial Bhumianl Kichurna, Haridra Khand, Kamdudla
Ras, Mahamanjisthadi KwathTab,
Arogyavardhini Tab, Tagaradi Vati
Miscellaneous Mixed (2.7) Death 124
13 62 Female White 1) Cellular Research Formulas Dual Action
Cleanse-Colon Clear Formula
2) Cellular Research Formulas Multicleanse
Formula-Cleansing Complex with Herbs
3) Cellular Research Formulas Multicleanse
Formula-Cleansing Complex with Fibers
4) Cellular Research Formulas Dual Action
Cleanse-Total Body Purifier
Miscellaneous Cholestatic (<1) Transplant 263
Table 2. Outcomes
Outcome
Liver Injury Caused
by Bodybuilding
HDS (n5 45)
Liver Injury Caused
by Nonbodybuilding
HDS (n5 85)
Liver Injury Caused
by Conventional
Medications (n5 709) P Value
Hospitalization (%) 32 (71) 58 (68) 414 (58) 0.069
LT at any time after onset on injury (%) 0 (0) 11 (13) 24 (3) <0.001
Death at any time after onset of injury (%) 0 (0) 3 (4) 50 (7) 0.095
Severe/fatal per DILIN severity score (%) 6 (13) 30 (35) 181 (26) 0.02
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with strikingly elevated total serum bilirubin levels and
only modest increases in ALT, AST, and ALP values,
yet the R value at study entry classified 42% of them
as having a hepatocellular pattern of injury. On the
other hand, most patients with injury caused by non-
bodybuilding HDS and medications had R values
(>5) indicative of hepatocellular injury.
Course of Liver Injury. Latency, defined as the
number of days between start of the agent and onset
of injury, was not significantly different among the
three groups (Table 4), although there was substantial
variability. In contrast, patients with hepatotoxicity
from bodybuilding HDS had a more protracted course
of liver injury (assessed as the median number of days
Table 4. Clinical and Laboratory Data
Characteristic
Liver Injury Caused
by Bodybuilding
HDS (n5 45)
Liver Injury Caused
by Nonbodybuilding
HDS (n5 85)
Liver Injury Caused
by Conventional
Medications (n5 709) P Value
Weight (kg) <0.001
Median 86.4 72.7 74.1
(25th, 75th) (78.7, 98.1) (62.8, 83.6) (62.4, 89.4)
BMI 0.954
Median 26.4 6.2 26.2
(25th, 75th) (24.3, 29.5) (23.1, 30.2) (22.9, 30.4)
Symptoms (%)
Jaundice 45 (100) 66 (78) 482 (68) <0.001
Nausea 27 (60) 56 (66) 420 (59) 0.522
Pruritus 38 (84) 41 (48) 373 (53) <0.001
Fever 7 (16) 17 (20) 208 (29) 0.033
Abdominal pain 26 (58) 44 (52) 293 (41) 0.024
Rash 11 (24) 18 (21) 190 (27) 0.553
Any comorbid medical condition* (%) 9 (21) 45 (53) 492(69) <0.001
Diabetes 0 19 (22) 192 (27) <0.001
Neurological disease 3 (7) 6 (7) 125 (18) 0.007
Heart disease 1 (2) 9 (11) 150 (21) <0.001
Pulmonary disease 3 (7) 9 (11) 142 (20) 0.009
Gastrointestinal disease 4 (9) 24 (28) 252 (36) <0.001
Any alcohol use (%) 34 (79) 45 (54) 338 (48) <0.001
Liver enzymes at onset
ALT (U/L), median 173 1019 505 <0.001
(25th, 75th) (124, 376) (360, 1,695) (249, 965)
AST (U/L), mean 82 815 319 <0.001
(SD) (65, 118) (323, 1437) (167, 852)
ALP (U/L), mean 116 212 222 <0.001
(SD) (92, 133) (153, 283) (142, 269)
Total bilirubin (mg/dL), mean 9.8 7.5 4.3 <0.001
(SD) (7.8, 13.0) (3.0, 13.0) (1.1, 8.0)
Clinical pattern at onset* (%) 0.012
Cholestatic 12 (28) 10 (13) 164 (25)
Mixed 13 (30) 13 (17) 150 (23)
Hepatocellular 18 (42) 56 (71) 351 (53)
Days from start of medication or HDS to signs
or DILI onset, median (25th, 75th)
43.5 (25.5, 74.5) 30.0 (11.0, 59.0) 26.0 (11.0, 79.0) 0.157
Course of Injury, median
ALT† 28 14 13 <0.0002
(25th, 75th) (11,115) (6, 26) (7, 25)
AST† 52 11 10 <0.001
(25th, 75th) (12,135) (4, 25) (5, 21)
ALP† 126 60 43 0.035
(25th, 75th) (42,229) (23,179) (21,154)
Total bilirubin‡ 91 44 35 <0.001
(25th, 75th) (54, 173) (27, 92) (15, 66)
Comorbid medication conditions included endocrine, infectious, psychiatric, neurological, cardiac, renal, pulmonary, gastrointestinal/hepatic, malignant, and auto-
immune diseases.
*Cholestatic was defined as an R value< 2, mixed as R value 2-5, and hepatocellular as R value >5.
†Median number of days for the liver test to fall to 50% of its peak value based on time-to-event analysis.
‡Median days from peak to <2.5 mg/dL.
Abbreviation: SD, standard deviation.
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to achieve a 50% reduction from the peak ALT and
AST abnormalities and from the peak total bilirubin
level to less than 2.5 mg/dL) than did the other two
groups. Patients with liver injury from bodybuilding
HDS were jaundiced for a median of 91 days, com-
pared to 44 and 35 days, respectively, for the nonbo-
dybuilding HDS and medication groups (P< 0.001).
Supplements Implicated in Liver Injury. The
majority of patients used numerous HDS products,
most of which contained multiple ingredients, includ-
ing vitamins, minerals, and botanical extracts. Thus,
the 130 patients with liver injury from bodybuilding
and nonbodybuilding HDS reported that they had
taken a total of 217 products. Among these 217 prod-
ucts, 175 (81%; 59 bodybuilding HDS and 116 non-
bodybuilding HDS) had identifiable ingredients. Only
7 (12%) of the 59 bodybuilding HDS and 25 (22%)
of the 116 nonbodybuilding HDS were labeled as hav-
ing a single component, whereas 6 (10%) bodybuild-
ing and 15 (13%) nonbodybuilding products had
more than 20 ingredients. The list of implicated HDS
products is shown in Supporting Table 1.
Discussion
Contrary to widespread belief, this study demonstrates
that HDS products are not always safe. Indeed, our data
suggest that, relative to conventional medication-induced
hepatotoxicity, liver injury from HDS not only occurs,
but also may be increasing in frequency over time in the
populations surrounding the DILIN centers and, prob-
ably, in the United States as a whole. The study also
shows that bodybuilding HDS are the most commonly
implicated class of products. Most important, we found
that nonbodybuilding HDS can cause liver injury that is
more severe than conventional medications, as reflected
in a higher transplantation rate. This finding was inde-
pendent of comorbid conditions.
Regarding nonbodybuilding HDS, despite their het-
erogeneity, the typical pattern of liver injury was hepa-
tocellular, similar to acute viral hepatitis. This injury
occurred most often in women. Clearly, the evidence
of acute necroinflammatory liver injury, reflected in
the high ALT and AST levels and the R value, identi-
fies a greater degree of hepatocyte injury, predisposing
to more-serious outcomes.
Data from other countries have also noted the
occurrence of HDS-related liver injury, ranging from
2%13 to 16% of all identified cases of hepatotoxicity,14
but such reports have not reported a temporal trend.
Our observation of the rising burden of hepatotoxicity
attributed to HDS in the DILIN coincides with their
increasing use in the United States. In 1990, 34% of
U.S. adults used some form of alternative therapies,
2.5% being herbals or dietary supplements.15 By
1997, the frequency had increased to 42%, 12% using
herbals. The NHANES II survey showed a 35% preva-
lence of supplement use between 1976 and 1980,16
rising to 52% in the 1999-2000 survey.3 Between
1988 and 1994, the increased use was not gender spe-
cific, with rates in men increasing from 30% to 42%
and in women from 42% to 55%.17 As noted, recent
data show that approximately half of U.S. adults use
dietary supplements.1,2
The increased use of HDS is also reflected in com-
merce. An estimated $27 billion was spent by consum-
ers for all herbal products in 1997.16 This figure rose
to $33.9 billion in 2007.18 Additionally, reports from
the American Botanical Council showed that sales of
herbals increased from 1999 to 2011.19 These data,
allied with our findings, suggest that the incidence of
hepatotoxicity from HDS is increasing and is likely to
continue to increase. However, the DILIN is not a
population-based study and our data may reflect geo-
graphical variations in usage patterns.
Our analysis revealed bodybuilding products to be
the most common cause for liver injury among those
using HDS products, eliciting a distinctive clinical pic-
ture of prolonged jaundice in young men with nonfa-
tal outcomes. Despite the prolonged jaundice and only
modest increases in ALT or AST values, the initial R
values suggested hepatocellular injury in a substantial
proportion. This may reflect a shortcoming of the R-
value determination or of the threshold of >5 as
defining hepatocellular injury, or there may indeed be
early hepatocellular injury from bodybuilding HDS. In
fact, a recent report of liver injury resulting from the
product, N.O.-XPLODE, ostensibly a bodybuilding
(muscle-enhancing) product, showed that one third of
patients affected had hepatocellular patterns of
injury.20 A planned comparison of the R value to the
histological findings may further clarify this point.
Another important consideration is that there is no
standard nomenclature or classification schema for
HDS; therefore, the process of grouping various HDS
by their intended effect may be flawed, because it does
not take into account ingredients and their potential
mechanisms of action or injury.
There are numerous reports of liver injury from
bodybuilding products, some shown or suspected to
contain anabolic steroids.21-23 The similarity in the
pattern of injury in the bodybuilding group in this
study with those reported previously suggest that there
may be a common susceptibility factor or that the
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products may contain 17-alkyl substituted (anabolic)
steroids, which are well known to cause this injury
pattern.24 Alternatively, host susceptibility factors, such
as drug- or ingredient-specific genetic determinants of
drug disposition, may account for the injury.25-27
Assessing potential HDS hepatotoxicity presents
unique challenges. The numerous products that fre-
quently contain multiple ingredients, often with unclear
chemical descriptors and variable common names, can
confound pinpointing the specific toxic agent. Further-
more, some products may seem quite innocuous, such
as multivitamins, making it difficult to conceive of any
toxic potential. There are many reports of contamina-
tion of herbals with microbials,28,29 pharmaceuticals,30-
32 mycotoxins,33 and heavy metals.34-37 Also, unidenti-
fied interactions with medications used concomitantly
may be responsible for toxicity, yet are difficult to estab-
lish. Although the causality assessment process gave us
confidence that our cases, in fact, represented bona fide
hepatotoxicity from HDS, any one of these factors
could have been present.
Our findings underscore our still rudimentary
understanding of liver injury from HDS and create a
mandate for further research into their safety. Although
we demonstrate that numerous HDS products have
the capacity to cause liver injury and such injury is
more likely to result in transplantation than injury
from conventional medications, identifying the specific
ingredient responsible for the injury, or perhaps even
permissive host factors, remains a daunting challenge.
The most effective approach to identify culprit agents
would require a painstaking separation of products
into their component ingredients, followed by in vitro
and in vivo toxicological evaluation. Arguably, the cost
of such an extensive approach would be prohibitive to
most funding agencies. Alternatively, an effort to list
every identifiable ingredient in all implicated HDS
products and confining toxicological analysis to those
ingredients that appear frequently among such prod-
ucts might represent a more focused and practical
approach. Large registries will be critical in continuing
to amass products for this purpose.
As noted, the DILIN is not a population-based
study, and although there was an increasing proportion
of disease attributable to HDS during the study, it
cannot be concluded that the problem is actually on
the rise in the United States. Therefore, population-
based studies to investigate the incidence of liver injury
will inform several avenues of future investigation and
regulation. Notwithstanding the need to accurately
determine the incidence of drug- and dietary-
supplement–induced liver injury in the United States,
a better understanding of the impact of the problem
on the population will permit proportionate allocation
of resources toward research. All stakeholders, includ-
ing the dietary supplement industry, regulatory agen-
cies, health care providers, and consumers, must take
note of these findings if a culture of safety for HDS
use is to be established.
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Appendix
State Enrolling Sites: California: California Univer-
sity of California, San Francisco, California Pacific
Medical Center; Connecticut: University of Connecti-
cut; Indiana: Indiana University; Michigan: University
of Michigan; Minnesota: Mayo Clinic; North Caro-
lina: University of North Carolina, Chapel Hill, Caro-
linas Medical Center; Pennsylvania: Einstein Medical
Center, University of Pennsylvania; Texas: University
of Texas, Southwestern.
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